SAGE - Sage Therapeutic - Stock Price & Dividends

Sage Therapeutics is a biopharmaceutical company that focuses on developing and commercializing innovative medicines to improve brain health. The company's lead product, ZULRESSO, is an intravenous injection approved for the treatment of postpartum depression (PPD) in adults. Additionally, Sage Therapeutics is developing ZURZUVAE, a neuroactive steroid that targets both synaptic and extrasynaptic GABAA receptors, also for the treatment of PPD.

The company's product pipeline is diverse and promising, with multiple compounds in various stages of clinical trials. SAGE-324, for instance, is being developed to treat essential tremors and has already completed Phase I clinical trials for epilepsy and Parkinson's diseases. Another compound, SAGE-718, is an oxysterol-based positive allosteric modulator of the NMDA receptor, which is being tested in Phase II clinical trials for a range of indications, including depression, Huntington's disease, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.

Sage Therapeutics has established strategic partnerships to accelerate the development and commercialization of its products. The company has a collaboration with Shionogi & Co., Ltd. to develop and commercialize zuranolone in Japan, Taiwan, and South Korea. Additionally, Sage Therapeutics has a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Sage Therapeutics has undergone significant transformation, including a name change from Sterogen Biopharma, Inc. to Sage Therapeutics, Inc. in 2011. The company's commitment to advancing brain health medicines has positioned it as a leader in the biopharmaceutical industry. For more information, visit their website at https://www.sagerx.com.